Mannosylated nanoparticle immunogens enhance the circumsporozoite protein-specific B cell response and improve protection against sporozoite challenge
McDougal, C. E.; Langowski, M. D.; Nikolaeva, D.; Chen, C.; Bangs, D. J.; Valdez, A.; Ravichandran, R.; Cheng, S.; Lofgren, M.; Dillon, M.; Sanders, D.; Molina-Cruz, A.; Idris, A. H.; Miura, K.; Lee, K.; Seder, R. A.; Pepper, M.; King, N. P.
Show abstract
Underprocessed oligomannose glycans on protein nanoparticle immunogens engage the innate immune system through mannose-binding lectin and complement, enhancing immunogen trafficking and B cell responses. However, the extent to which oligomannose glycans directly improve protective immunity has remained unclear. Here we generate a series of CSP-bearing I53-50 nanoparticle malaria vaccine candidates with defined numbers and types of engineered N-linked glycans and systematically evaluate their immunogenicity and protective efficacy. Oligomannose display enhanced early plasmablast and germinal center B cell responses, leading to increased CSP-specific memory B cells, long-lived plasma cells, and durable serum antibody titers. Furthermore, nanoparticles bearing oligomannose glycans conferred the strongest protection against sporozoite challenge. By comparing immunogens with defined glycoforms, we attribute improved immune responses and protection specifically to oligomannose rather than complex or truncated glycans. These results will help guide the development of general strategies for glycan engineering aimed at enhancing the protective efficacy of nanoparticle vaccines.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.